

FOR IMMEDIATE RELEASE

April 17, 2025

Tyson's Virginia

Kubanda Cryotherapy Wins "People's Choice Award" for Innovative Animal Tumor Detection Technology at Accelerate Breakfast Series

McLean, VA -- Kubanda Cryotherapy, a leading innovator in solutions for animal health, was awarded the coveted "People's Choice Award" at the Friday, April 11 Accelerate Breakfast Series event held at the Hyatt Regency in Tysons, VA. They were one of five entrepreneurs selected to pitch from a pool of more than 100 startups to an audience of nearly 200 as part of the Accelerate Breakfast series. These five companies ranged from space tech to fin-tech to veterinary medicine.

Kubanda's innovative approach to veterinary tumor treatment with minimally-invasive cryotherapy captured the attention of the Accelerate breakfast audience, comprised of entrepreneurs, investors, and business leaders across the DMV region. The company's groundbreaking work was recognized by attendees, who voted Kubanda as the winner of the coveted "People's Choice Award."

"We are honored to receive this award, which is a testament to the hard work and dedication of our team," said Bailey Surtees, CEO of Kubanda Cryotherapy. "Our mission is to leverage the power of cryotherapy to revolutionize the way we treat tumors and increase access to care for pets in every neighborhood, and this recognition underscores the importance and impact of our work."

Kubanda was spun out of Johns Hopkins by co-founders Bailey Surtees and Clarisse Hu. Their patented technology utilizes cutting-edge carbon-dioxide-based cryotherapy to treat tumors with targeted, extreme cold. The procedure can be done at a local vet's office without general anesthesia, unlocking treatment for the >90% of tumors that go untreated. The procedure is half the cost of traditional surgery, empowering vets and pet owners to take a more proactive approach to tumor management, increasing access to care for pets.

Blaire Rowe Rakowicz with Cross Impact Capital, who served as a member of the investor panel, said, "The Accelerate Breakfast brought together an exceptional group of founders building innovative solutions right here in the DMV. I continue to be impressed by the creativity and clarity of vision from Kubanda and the other four presenters—each demonstrating a compelling value proposition and a strong founder–market fit."

Dave Harvey, Executive Director for the Accelerate Breakfast Series said, "I know this was a difficult decision for the audience as all of the presentations were compelling -- which says a lot about the audience's choice of Kubanda. The company represents the type of innovative company we like to select that demonstrates patentable technology, an exceptional management team, and significant market traction."

The Accelerate Breakfast Series, held quarterly, brings together the region's most promising startups, investors, and industry leaders together to showcase innovative technologies and solutions. Each event offers an exciting platform to connect, collaborate, and discover high-potential investment opportunities from some of the area's fastest-growing tech companies. The next breakfast event will be held Thursday, July 10, 2025.

About Accelerate Breakfast Series:

The Accelerate Breakfast Series is a partnership between George Mason University and Fairfax County, designed to support early-stage companies throughout the greater Washington, D.C. region. Designed to unite entrepreneurs and investors by offering a curated platform for pitch opportunities and networking. Each event, held quarterly, highlights five selected high-growth startups, providing them a venue to showcase their ventures to a consortium of early-stage investors, and other business stakeholders. During these presentations, companies emphasize crucial aspects of their business models, growth trajectories, and distinctive value propositions. Participating companies are expected to actively seek seed-stage capital within the range of \$500,000 to \$2 million.

About Kubanda Cryotherapy:

Kubanda Cryotherapy, Inc. – Disrupting the \$4B veterinary tumor market with carbon dioxide-based cryotherapy, Kubanda provides the first affordable, minimally invasive treatment capable of treating large tumors for pets. Developed by cryobiologists and biomedical engineers, it has been launched in North American clinics to save time, reduce costs for pet owners, and improve clinic ROI.

###

Contact: Dave Harvey, Executive Director, Accelerate Breakfast Series

Email: dave@harveygc.com